Levolac

Quick links to important sections

Levolac

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Levolac

What is Levolac? Overview and Identity

The identity of Levolac is anchored in its active substance, Lactulose, a synthetic disaccharide that functions as a highly effective osmotic laxative. This foundational section defines the medicine by its type, composition, and general mechanism, strictly adhering to principles of absolute factual accuracy.

Property Description
Active ingredient Lactulose
Form Oral solution (syrup)
Pharmacological class Osmotic laxative / Prebiotic
Common use Managing impaired intestinal motility
Origin Synthetic disaccharide

What Type of Medicine is Levolac (Lactulose)?

Levolac is a gastrointestinal agent classified as an osmotic laxative, primarily used to support and manage impaired intestinal motility. Its core identity is a synthetic disaccharide whose single active ingredient is Lactulose. This oral solution, typically prepared as a syrup, is designed for ingestion to work locally within the lower digestive system and is often available over-the-counter (OTC), a feature that distinguishes its access profile.

This medicine belongs to the osmotic laxative group because its primary function is driven by its physicochemical properties. The compound’s unique synthetic origin, derived from galactose and fructose, ensures it is non-absorbable in the small intestine.


Composition and General Purpose of Levolac

The primary component of Levolac is Lactulose, which operates as a colon-specific compound that does not enter the bloodstream. The general purpose of this liquid preparation is to relieve intestinal discomfort by ensuring the stool is adequately softened, which is described as a suitable approach for individuals requiring gentle, non-stimulant bowel support.

The fundamental mechanism is rooted in the non-absorbable nature of the Lactulose compound. Once it reaches the large intestine, it draws water into the stool, increasing its overall volume and softness via an osmotic effect. The osmotic action of Lactulose increases the water content of the stool. This increased water content directly facilitates easier and more comfortable passage. A further benefit of the composition is that colonic bacteria ferment the Lactulose, producing beneficial mild acids; this dual activity also classifies Levolac as a prebiotic.

Regulatory References

  1. FDA DailyMed: Lactulose Solution

What side effects are possible with Levolac?

Possible Side Effects and Safety Information

The officially documented safety profile for Levolac (Lactulose) is primarily characterized by adverse reactions related to its localized action within the gastrointestinal tract. Serious adverse reactions are generally complications of excessive gastrointestinal fluid loss, not intrinsic effects of the compound at therapeutic doses.

Adverse Reactions and Frequency

Adverse reactions are classified according to frequency, primarily affecting the gastrointestinal system:

  • Very Common (ge 1 in 10 patients): Diarrhea.
  • Common (ge 1 in 100 to < 1 in 10 patients): Flatulence, abdominal pain, nausea, and vomiting.
  • Uncommon (ge 1 in 1,000 to < 1 in 100 patients): Electrolyte imbalance, which is documented as a consequence of unadjusted high-dose use leading to persistent diarrhea.

Transient effects, such as flatulence and abdominal cramps, are commonly observed at the initiation of treatment and typically resolve after a few days of therapy. Hypersensitivity reactions (e.g., rash, pruritus) are documented, but their frequency is classified as Not Known.

Specific Safety Constraints

The official labeling includes specific restrictions. The medicine is contraindicated in patients diagnosed with Galactosaemia or those on a low-galactose diet due to the minor presence of related sugars. Diabetic patients should use the medicine with caution, especially when long-term, high doses are required, such as in the treatment of portal-systemic encephalopathy. Furthermore, for elderly or debilitated patients on continuous treatment for chronic constipation for longer than six months, periodic monitoring of serum electrolytes is formally indicated in the labeling.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documents define the overdose profile for Levolac (Lactulose) by the severe clinical presentation resulting from excessive osmotic action.

Overdose Manifestations and Risks Official Regulatory Statements
Documented Manifestations The principal signs of overdosage are diarrhea, abdominal cramps, and abdominal pain.
Serious Risks Severe overdosage can lead to severe fluid loss and critical electrolyte depletion, including documented cases of hypokalemia and hypernatremia.
Vulnerable Population Regulatory prescribing information notes that infants may be particularly susceptible to dehydration and hyponatremia following an overdosage.

Emergency Action Required

If an overdosage is suspected, regulatory guidance mandates immediate and specific action:

  • Seek immediate medical attention and/or contact a Poison Control Center or emergency department immediately.
  • The medicine must be stopped, and management focuses on providing symptomatic treatment and addressing the consequences of the fluid imbalance.
  • Fluid and electrolyte replacement is the necessary supportive measure for extensive fluid loss.
  • No specific antidote is known for Levolac overdose; treatment is supportive.

The requirement to seek urgent medical attention is strictly tied to the life-threatening metabolic risks posed by severe fluid loss and electrolyte depletion, which necessitate professional clinical monitoring and intervention.

Therapeutic Uses of Levolac

Quick Facts

  • Main Uses: Management of constipation; reduction of blood ammonia levels.
  • Benefits: May support the softening of stools; may assist in facilitating bowel movements; may help maintain mental status in certain conditions.

What Levolac Treats: Main Uses and Benefits

Levolac (also known by its generic name, lactulose) is indicated for two primary therapeutic domains. The first key use is the management of chronic constipation. In this role, the medication may assist in relieving difficulty in having bowel movements. It works to draw water into the colon, which supports the softening of stools and may facilitate bowel movements.

Secondly, this product may be used to prevent and treat a condition related to severe liver disease known as portal-systemic encephalopathy (PSE), which can involve changes in mental status. For patients managing this condition, Levolac may assist by reducing the amount of certain toxins, such as ammonia, in the blood, which is a factor in this condition.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Levolac (lactulose) is an osmotic laxative used to treat constipation and Hepatic Encephalopathy (HE) in adults. Its eligibility for use is clearly defined by regulatory documents based on patient conditions.

Populations Who Must Not Use Levolac (Contraindications)

Levolac is strictly contraindicated for patients with:

  • Galactosaemia (a severe genetic disorder that prevents galactose metabolism).
  • Hypersensitivity (allergy) to the active substance (lactulose) or any excipients.
  • Acute inflammatory bowel disease (such as Crohn's disease or ulcerative colitis).
  • Gastro-intestinal obstruction or subocclusive syndromes.
  • Digestive perforation or a high risk of perforation.
  • Painful abdominal symptoms of undetermined cause.

Populations Requiring Special Consideration

Population / Condition Eligibility Status Key Restriction
Pediatric Patients (1 month to 17 years) Allowed for constipation only Use should be exceptional and under medical supervision. Safety and efficacy for HE are not established.
Diabetes Mellitus Use with caution The medication contains small amounts of sugars (lactose/galactose); this may need to be considered, especially at the high doses used for HE.
Pregnancy / Lactation Allowed (if necessary) Systemic exposure to lactulose is negligible, meaning no effects on the fetus or breastfed infant are anticipated.
Renal or Hepatic Impairment Allowed (No special dose adjustment) Use with caution in patients prone to electrolyte disorders (e.g., those with renal impairment), especially with chronic high-dose use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of Levolac (Lactulose) around pharmacodynamic effects and local interference, as systemic absorption is minimal. The product is contraindicated for patients with the pre-existing condition galactosemia due to the presence of trace residual sugars in the formulation.

Documented Pharmacodynamic and Functional Interactions

Interacting Product Category Official Interaction Statement Regulatory Restriction Type
Potassium-Losing Agents (e.g., Thiazide diuretics, Corticosteroids, Amphotericin B) Co-administration may increase the potential for potassium loss (hypokalemia). Monitoring/Caution
Cardiac Glycosides Hypokalemia caused by lactulose may potentiate the effects of co-administered glycosides. Monitoring/Caution
Non-absorbable Antacids Concurrent use may result in a lack of therapeutic effect by inhibiting the necessary drop in colonic pH. Effect Interference
Non-absorbable Anti-infective Agents The use of antibiotics that act locally in the gut is noted as theoretically counterproductive. Effect Interference

For patients undergoing endoscopic procedures, such as colonoscopy or proctoscopy with electrocautery, a thorough bowel cleansing with a non-fermentable solution is required. This procedural restriction addresses the theoretical risk associated with the accumulation of fermentable gases produced by lactulose within the colon. Additionally, the regulatory label notes that for individuals on long-term use (exceeding six months), monitoring of serum electrolytes may be appropriate.

Mechanism of Action

How Levolac Works

The mechanism of Levolac, whose active substance is the synthetic disaccharide Lactulose, is defined by a unique dual action that works locally within the large intestine. As the molecule is non-absorbable in the small intestine, it reaches the colon intact, where its function relies entirely on two complementary physiochemical and biological processes.

First, the colonic microbiota ferments the Lactulose into Short-Chain Fatty Acids (SCFAs). The presence of the unabsorbed molecule and these acidic byproducts creates an osmotic gradient within the lumen, which alters water transport from the surrounding tissues. The primary physiological consequence is the increased hydration and volume of the intestinal contents.

Second, the SCFA production significantly lowers the intraluminal pH. This acidification initiates a chemical ion trapping cascade, converting the unionized ammonia ( NH3) into the non-absorbable ammonium ion ( NH4^+). The resulting physiological effect is the decreased passive diffusion of ammonia into the systemic circulation as NH4^+ is promoted for faecal excretion. This entire mechanism is rate-limited by the time required for bacterial fermentation, dictating a delayed onset of approximately 24 to 48 hours.

Dosage and Administration Information

How Levolac is Used: Administration Guidelines

The usage of Levolac (Lactulose) is characterized by specific parameters regarding the proper route, dosage, and administration context for its approved indications.

Administration Routes and Forms

Levolac is primarily administered via the oral route as a solution (syrup) or powder. An alternative rectal route, utilized as a retention enema, is specifically reserved for the treatment of severe cases of Portal-Systemic Encephalopathy (PSE), particularly in patients who are comatose or pre-comatose.

Standard Dosing and Frequency Patterns

Dosing schedules are specific to the condition being managed. For the management of chronic constipation, the typical regimen is once daily, with an initial oral dose ranging from 15 mL to 30 mL (10 g to 20 g). For the treatment of PSE, a more frequent schedule is used, with oral maintenance doses generally administered three or four times daily. The maximum daily oral dose for constipation may be increased up to 60 mL (40 g).

Contextual Use and Duration

The oral solution can be taken with or without food and may be diluted with liquids such as water, juice, or milk to improve its palatability. A key administration principle is the time required for effect: the desired laxative action typically occurs only after 24 to 48 hours. For PSE, therapy often begins with a high initial bolus and transitions to a continuous long-term maintenance regimen, with the dose adjusted to produce a specific target of two to three soft stools daily. If the initial dose causes diarrhea, the dose must be immediately reduced.

Recent Clinical Evidence

Research Evidence Overview for Levolac (Lactulose)

Research provides context about what has been observed so far in study populations, but does not offer advice or guarantees about individual outcomes. This section summarizes the types of clinical studies, patient groups, and specific outcomes examined by researchers for the licensed uses of the medicine, drawing from regulatory documents and peer-reviewed scientific literature.


Evidence for Use in Managing Chronic Constipation

Studies exploring the role of lactulose for conditions characterized by functional limitations have primarily used short-term Randomized Controlled Trials (RCTs) and systematic reviews to aggregate findings. Researchers in these trials primarily focused on objective measures used in research exploring how symptoms change over time. They monitored the change in weekly stool frequency and used standardized scales to assess stool consistency. Multiple trials reported measurements related to whether weekly stool frequency changed when comparing the compound to an inactive control (placebo).

Studies Comparing Lactulose to Other Agents

Comparative research has explored how lactulose performs against other types of osmotic laxatives. Findings were mixed across studies, with some comparative trials describing patterns where measured outcomes differed between the compound and other osmotic agents. This evidence contributes to the broader evidence landscape by helping contextualize how patients reported their experience when using different therapies.

Evidence for Use in Portal-Systemic Encephalopathy (PSE)

Lactulose was studied for its role in managing Portal-Systemic Encephalopathy (PSE), a condition associated with outcomes related to systemic or functional imbalance due to severe liver disease. The research base includes RCTs and systematic reviews. Studies monitored key clinical outcomes, including shifts in blood ammonia levels and evaluations of mental status and cognitive function using specific psychometric tests. Findings describe patterns observed in the studies where the compound's use was associated with differences in measured outcomes, including mortality risk and the incidence of HE events, when compared to controls or other treatments.

What Research Gaps and Uncertainty Exist

Certain research limitations are documented in the scientific literature. Follow-up durations were limited in many constipation studies, meaning the data for long-term outcomes are not fully established. Additionally, comparative evidence is lacking in some areas, and the ethical constraints of withholding a standard treatment like lactulose in severe conditions like HE mean that recent, large-scale, placebo-controlled trials are often difficult to conduct.

Key Studies & References

  1. The treatment of chronic constipation in adults: a systematic review
  2. Therapeutic Duel of Rifaximin Versus Lactulose in Hepatic Encephalopathy: A Systematic Review
  3. Lactulose Solution (Encephalopathy) - Cleveland Clinic (based on FDA/Regulatory language for indications)

Frequently Asked Questions (FAQ)

Common questions about Levolac (FAQ)

Q: How quickly can a person expect Levolac to start working?

The onset of the desired effect from Levolac typically takes 24 to 48 hours. This delayed action occurs because the active ingredient must travel to the colon and be broken down by local bacteria before it can exert its osmotic effect. Official information describes the typical time frame for effect as 24 to 48 hours.

Q: Can Levolac be taken by children?

According to official guidance, Levolac is allowed for use in pediatric patients but is strictly limited to the treatment of constipation. Its use in children is generally described as exceptional and is formally indicated to be carried out under the careful supervision of a healthcare professional.

Q: Is Levolac safe for pregnant people to use?

Official product information states that systemic exposure to the active substance is negligible. As a result, no effects on the fetus are anticipated. However, like any medication used during pregnancy, its appropriateness is a factor for consideration in consultation with a healthcare provider.

Q: Does Levolac affect blood sugar levels, especially for people with diabetes?

The medicine contains trace amounts of residual sugars, such as lactose and galactose. Official labeling notes that people with diabetes must consider the product with caution, particularly when continuous or high-dose therapy is required, such as in the treatment of Hepatic Encephalopathy.

Q: Can older adults use Levolac without special concerns?

Levolac is generally allowed for use in older adults. However, official safety constraints note a specific consideration for elderly or debilitated patients on continuous treatment for chronic constipation lasting longer than six months. In these cases, formal regulatory guidance specifies that periodic monitoring of serum electrolytes is formally indicated.

Q: Can Levolac be used while breastfeeding?

Official product information confirms that the use of Levolac is generally allowed while breastfeeding. This is because systemic exposure of the active substance in the mother is considered negligible, meaning no effects on the breastfed infant are anticipated.

Q: Is Levolac the same thing as other popular treatments for the same condition?

No, Levolac is not functionally the same as every other product available for similar conditions. Official documents classify the active ingredient as a synthetic disaccharide that works as an osmotic laxative and a prebiotic. Its unique mechanism is dependent on drawing water into the colon and being fermented by local bacteria, which differs from stimulant laxatives.

Q: Is it okay to take Levolac for a long time, like several months?

For the treatment of severe liver conditions like Hepatic Encephalopathy, long-term, continuous use is a recognized and official regimen. For chronic constipation, official product information indicates that continuous use exceeding six months may require a specific safety measure: the periodic monitoring of serum electrolytes.

Q: Are there any common foods or drinks I should avoid while taking Levolac?

Official regulatory documents state that the oral solution can be taken with or without food and may be diluted with common liquids like water, juice, or milk. The medicine’s interaction profile focuses primarily on specific classes of medications, with no official warnings concerning interactions with common foods or beverages.

Q: Is Levolac a prescription-only medicine?

Levolac is commonly available over-the-counter (OTC) for the management of constipation. However, when the medicine is used at high dosages for the management of severe conditions, such as Hepatic Encephalopathy, it is typically accessed via prescription.

Q: Why is Levolac sometimes used for conditions other than the main use?

Official regulatory documents define the medicine's approved use as strictly limited to two specific indications: the treatment of chronic constipation and the management of Portal-Systemic Encephalopathy (PSE). Regulatory bodies do not provide information or guidance on any uses outside of these two approved conditions.

Q: Are there any age restrictions for who can use Levolac?

It is approved for use across a wide range of adults. For children, use is allowed for constipation but only under specific medical supervision. Regulatory guidance further specifies that special monitoring may be indicated for elderly or debilitated patients on prolonged therapy.

Q: Has there been much research done on the long-term safety of Levolac?

Research evidence published in the scientific literature indicates that follow-up durations were limited in many studies evaluating the medicine for constipation. This means that data confirming very long-term outcomes and safety are not fully established in research findings.

Q: Can Levolac be used by people who have lactose intolerance?

The medicine is specifically contraindicated only for those with Galactosaemia, a severe disorder requiring a low-galactose diet. However, because the solution contains trace amounts of lactose (the sugar in milk), an individual with lactose intolerance must consider this fact for discussion with a healthcare provider.

Q: Is it possible to take too much Levolac?

Yes. Taking an excessive amount can lead to common side effects like severe diarrhea and abdominal cramps. This unadjusted high-dose use can, in turn, cause complications such as the loss of body fluids and potential imbalances in key electrolytes like potassium ( hypokalemia) and sodium ( hypernatremia).

Q: What should I do if I think I am experiencing a rare side effect from Levolac?

Patient information sheets detail the procedure that any unusual, severe, or rare reactions must be addressed by contacting a healthcare provider. Patients are also encouraged to report the reaction to the relevant regulatory authority or official drug safety monitoring program in their country.

Q: Does Levolac affect the way my body absorbs other nutrients?

The active ingredient is highly localized in its action and is poorly absorbed from the small intestine, meaning it reaches the colon virtually unchanged. Its primary mechanism of action involves local water transport and ammonia clearance. Official regulatory mechanisms do not document a specific, direct effect on the absorption of other key nutrients.

Q: Is Levolac considered a stimulant or does it work naturally?

According to its official pharmacological classification, Levolac is defined as an osmotic laxative and a prebiotic. It is not classified as a stimulant because its action is driven by drawing water into the colon and being fermented by bacteria, rather than directly stimulating muscle movement.

Q: Are there any lifestyle changes that make Levolac work better?

Official patient information sheets contain the advisory statement to take the dose along with plenty of water. This is consistent with its mechanism as an osmotic laxative, which relies on fluid movement to achieve its full effect.

Q: Do studies show Levolac is effective for its intended use?

Yes. Studies have examined its effectiveness for both approved uses. Research for chronic constipation involved monitoring measures like weekly stool frequency. For Hepatic Encephalopathy (HE), research findings describe associations with positive changes in measured outcomes, including blood ammonia levels and mental status.

Q: What is the experience of patients who use Levolac for a prolonged period?

For continuous use exceeding six months, particularly in elderly or debilitated patients, regulatory guidance formally indicates that periodic monitoring of serum electrolytes may be appropriate. This is a safety measure to help mitigate potential fluid and salt imbalances that may occur with chronic use.

Q: Can people with kidney problems use Levolac?

Use in patients with renal (kidney) impairment is generally allowed, with official guidance noting that no special dose adjustment is typically required. However, caution is advised for any patient prone to developing electrolyte disorders, which may occur with chronic high-dose use.

Q: Can I take Levolac if I have a known heart condition?

Official warnings focus on the risk of electrolyte imbalance, specifically hypokalemia (low potassium), which can be caused by excessive diarrhea from high doses. Hypokalemia may potentiate the effects of certain co-administered heart medications, such as cardiac glycosides.

Q: How does Levolac affect the gut microbiome?

Levolac is officially classified as a prebiotic. Its mechanism relies on it reaching the colon and being fermented by the natural colonic bacteria (the gut microbiome) into beneficial substances known as Short-Chain Fatty Acids ( SCFAs).

Q: Does Levolac interfere with the absorption of birth control pills?

Official drug interaction lists do not specify a direct interference with oral contraceptive pills. However, regulatory patient information notes that if the medicine causes severe diarrhea or vomiting, this may potentially reduce the absorption and effectiveness of other oral medications, including birth control pills.

Q: Can Levolac be taken on an empty stomach?

The official regulatory label states that the oral solution may be taken with or without food. It can also be diluted with common liquids like water or juice.

How should Levolac be stored and disposed of?

How to Store and Dispose of Levolac (Lactulose Solution)

The following requirements ensure the product's quality and safety, based on regulatory labeling.

Storage Requirements

  • Temperature: Store at controlled room temperature, typically below 25 C (77 F) or 30 C (86 F). Do not allow the solution to freeze. Do not refrigerate, as this can cause crystallization.
  • Protection: Keep the bottle tightly closed and protect it from direct light and excessive heat or moisture.
  • Child Safety: Medication must be stored out of the sight and reach of children.

Disposal Instructions

  • Procedure: Do not dispose of expired or unused Levolac via wastewater (e.g., flushing down a toilet or pouring down a sink) or household trash.
  • Collection: Consult a pharmacist or local regulatory body for guidance on returning the product to a designated collection point or pharmacy take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Levolac found in:

A-Z Index: